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ABSTRACT. A new 20% safflower oil emulsion was studied in
a small series of pediatric patients. Eight infants and children
were evaluated over a 2-week period. The 20% fat emulsion
supplied a major portion of daily caloric requirements. No
serious side effects or toxicity were noted. No major changes in
blood chemistries were observed; however, a statistically sig-
nificant increase in serum albumin was noted. In addition, 63%
of the patients gained weight during the study. This investiga-
tion supports the contention that 20% Liposyn is a safe and
effective component of a parenteral nutrition program for chil-
dren.
Total parenteral nutrition (TPN) programs routinely
incorporate intravenously administered fat emulsions as
a major nutritional component. In addition to providing
essential fatty acids, fat emulsions also provide a concen-
trated source of energy substrates in an isotonic solution.
These properties are important in the infant population
in whom renal function limitations and glucose intoler-
ance may negate the sole use of large volume glucose and
amino acid (AA) solutions for IV nutrition. 
1
TPN regimens consisting solely of glucose and AA
require prohibitively large fluid volumes if sufficient ca-
loric intake necessary for growth is desired.’ The supple-
mentation of a portion of the TPN regimen with a fat
emulsion providing 30-50% of the total caloric require-
ments makes peripheral TPN both an attractive and
practical form of IV nutrition.3. 4 .
Having safely tested a safflower oil-based emulsion
(Liposyn) at both 10 and 20% concentrations in two
groups of pediatric patients, we proceeded to further
evaluate Liposyn 20% as a major component of a par-
enteral feeding prograM5’ ’ This study was designed to
document the efficacy of 20% Liposyn in children being
managed with a parenteral feeding regimen.
MATERIALS AND METHODS
This study was conducted at the Mott Children’s Hos-
pital in the University of Michigan Medical Center from
March through October, 1980.
Infants and children from 2 days to 12 years of age
requiring TPN for a minimum of 2 weeks were candidates
for the study. Patients demonstrating disturbances in
normal fat metabolism such as pathological hyperlipe-
mia, lipoid necrosis, or acute pancreatitis, if accompanied
by hyperlipemia, were excluded from the study. Patients
were allowed enteral calories during the course of study.
Eight children completed the study (Table I).
After parenteral informed consent was obtained, the
following preinfusion tests were performed: urinalysis,
complete blood count with differential white blood cell
count, platelet count, blood urea nitrogen, serum uric
acid albumin total protein, cholesterol, triglycerides, total
bilirubin, alkaline phosphatase, LDH, and SGOT. Sub-
clavian vein catheterization was performed on patients 1,
3, and 5 while peripheral venous access was established
in the remaining children.
All patients were begun on a TPN program of glucose,
AA, and a safflower oil emulsion (Liposyn 20%). The lipid
emulsion was infused through a Y-connector into the line
containing the glucose-AA solution and the infusion was
continuously administered over a 24-hr period. The so-
lution for centrally administered TPN consisted of 25%
glucose and 3.5% crystalline AA (Aminosyn, Abbott Lab-
oratories) while the peripheral regimen consisted of 12.5%
glucose and 2.5% crystalline AA (Aminosyn). The TPN
solution also contained routine vitamin and mineral ad-
ditives which are summarized in Table II. The composi-
tion of Liposyn 20%, which provides 2.0 kcal/ml, has
been previously reported.5, 6
All data was statistically analyzed using Student’s t-
test with p values less than 0.05 considered significant.
Table III summarizes the TPN protocol and includes
calculations of the average daily amount of various nu-
trients provided during the course of the study. Daily
observations included vital signs, weight, and a report of
advese symptoms or side effects. Estimated caloric re-
quirements were computed daily and were compared to
calories actually received. At weekly intervals, the initial
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TABLE I
Baseline data on 8 children receit-ing 20% Li~syn
TABLE II
Guidelines for TPN additive
&dquo; Trace element solution (manufactured by University of Michigan
Pharmacy Department: each ml contains: zinc, 2 mg (0.060 mEq);
copper, 0.4 mg (0.030 mEq); manganese, 0.2 mg (0.015 mEq); iodide,
0.056 mg (0.00044 mEq).
battery of blood and urine tests was repeated and an




Patients 2, 3, and 6 experienced an average weight loss
of 7.9 ± 4.6%, while the remaining patients exhibited an
average weight gain of 15.4 ±m 13.8% throughout the
course of the study period. The mean weight change at
the conclusion of the study was +6.7 ± 16.7%. This weight
gain was not significantly different from the baseline
measurements.
Serum albumin (Table 7~)
All patients entered the study with abnormally low
serum albumin levels. At the end of the study period,
patient 8 had a further decrease in serum albumin, pa-
tient 4’s value increased from baseline level but was still
abnormally low, patient 2 remained unchanged and the
remaining children showed marked increases in serum
albumin levels to within the normal range. Mean serum
albumin levels at the conclusion of the study period were
significantly increased from the baseline values.
Serum Triglycerides (Table IV9
Baseline serum triglyceride levels were abnormally low
in patient 1, abnormally high in patient 6, and normal in
the rest. At the conclusion of the study period, triglyc-
eride levels were abnormally low in patient 4, normal in
patient 3, and abnormally high in the remaining children.
The mean increase of serum triglyceride levels at the end
of the study was significant.
Blood Urea Nitrogen (Table I V)
Patients 1, 3, 5, and 7 had abnormally low baseline
blood urea nitrogen (BUN) levels, patients 4’s was ab-
normally high, and the remaining baseline values were
within the normal range. At the conclusion of the study
period, patients 1 and 3 had abnormally low values, while
the remaining patients had BUN values within the nor- 1
mal range. However, the mean change from baseline
measurements was not statistically significant.
Serum Glutamic Dxaloacetic Transaminase (SGOT)
(Table IV)
In all patients, the baseline levels of SGOT were ab-
normally elevated. Patients 2 and 3 concluded the study
period with normal levels of SGOT; in the remaining
patients, the values remained abnormally elevated. The
mean change of SGOT values from baseline measure-
ments was not statistically significant.
Serum Lactic Dehydrogenase (LDH) r7’crhlE~ IV)
All patients started and finished the study period wit h
abnormally high serum LDH levels. However, no signifi-
cant changes occurred during the study.
Serum Alkaline Phosphatase (Table IV9
Patients 6 and 7 had normal baseline levels of serum
alkaline phosphatase and the remaining patients abnor-
mally high values. At the conclusion of the study period,
patient 1 had normal alkaline phosphatase levels while
the rest of the children finished the study with abnor-
mallB- elevated levels. statistical analysis indicated a
nonsignificant increase in mean alkaline phosphatase
levels at the conclusion of the study periud.
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TABLE III
Average daily nutritional components
TABLE IV
Changes in blood chemistries during the infusion of 20% Liposyn in 8 children
Total Serum Bilirubin (Table IV)
All patients except 1, 3, and 7 had abnormally elevated
baseline measurements of bilirubin. At the conclusion of
the study period, patients 3 and 7 retained normal levels,
whereas the remaining children had bilirubin levels
which were abnormally high. Mean changes were not
statistically significant.
DISCUSSION
The variable biological activity of commercial fat
emulsions makes it difficult to generalize about their
toxicity and efficacy in a parenteral nutrition program.’ 7
The available lipid emulsions have different fatty acid
compositions, and the effect of these combinations on
the nutritional efficacy of a TPN regimen is unknown.
Liposyn 20% offers the theoretical advantage of having
a higher concentration of essential fatty acids (linoleic
acid) than other commercial fat emulsions.
Two previous reports from this institution have veri-
fied that no serious side effects or toxicity occurred in
children receiving 10 or 20% Liposyn as part of a TPN
program.5, 6
In this study, the mean weight gain was not statistically
significant; however, 63% of the patients gained weight
at the conclusion of the study period. Once again, al-
though the mean BUN did not significantly change dur-
ing the observation period., 75% of the patients concluded
the study with BUN values in the normal range com-
pared with 38% of the patients at the beginning of the
study.
The mean serum albumin significantly increased from
abnormally low baseline values to normal levels at the
conclusion of the study period. All of the patients started
the study with moderate to severe deficits in serum
albumin, whereas 63% of the children finished with nor-
mal levels. This was the only statistically significant
improvement in nutritional parmeters documented in
this investigation.
There were no significant increases in mean SGOT,
LDH, or bilirubin during the observation period. How-
ever, the majority of the patients concluded the study
period with elevated levels.
There was an increase in mean alkaline phosphatase,
an observation noted in other studies of patients treated
with and without fat emulsions.’
Serum triglyceride levels were abnormally elevated in
63% of the patients at the conclusion of the study period,
and the mean serum triglyceride level was significantly
increased from baseline measurements. Changes in se-
rum cholesterol and triglycerides with different fat emu
sions have been variable, and the transient elevations in
serum triglycerides noted in this study are consistent
with the findings of other studies in which different
emulsions were used.9, 10
No instance of the &dquo;overloading syndrome,&dquo; reported
with other preparations, was observed nor was fatty acid
deficiency documented in any of the patients studied. 11
The positive trends in weight gain and BUN levels
coupled with significant improvement in serum albumin
values document the improved nutritional status of these
patients.
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The significant, although mild, increases of both the
mean serum triglyceride and alkaline phosphatase levels
are consistent with the findings of preivously reported
studies. No other significant differences were noted dur-
ing the TPN therapy. Although the number of patients
in this study is small, the above findings together with
the absence of serious side effects or toxicity support the
conclusion that Liposyn 20% is a safe and relatively
effective component of a parenteral nutrition program
for children.
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